Quick answer
Mounjaro and Zepbound are Eli Lilly's FDA-approved brands; research-grade tirzepatide is a separate laboratory reagent with no Lilly affiliation.
- Molecule: 39-residue GIP-based dual GIP/GLP-1 agonist, ~4,813.52 Da, C20 diacid at Lys20
- Verification: HPLC, intact mass, and peptide mapping for the acylation site
- Records: cite generic name and lot, never a brand name
- V8 Peptides: 30 mg vial on the tirzepatide page; CoA page
- Research use: For laboratory research use only; not for human consumption.
For laboratory research use only; not for human consumption.
Brand names versus the molecule
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist, structurally based on the native GIP hormone with engineered cross-reactivity for the GLP-1 receptor. It is the active molecule behind Eli Lilly's FDA-approved pharmaceutical products. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company, and they refer exclusively to its FDA-approved pharmaceutical formulations (Mounjaro for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea). This article uses the brand names only to explain what is, and is not, being discussed.
Research-grade tirzepatide sold for laboratory use is a separate class of product. It is not manufactured, distributed, tested or endorsed by Eli Lilly, and V8 Peptides has no affiliation, partnership or commercial relationship with Eli Lilly or either brand. This article discusses tirzepatide strictly as a research compound and does not describe or compare pharmaceutical products intended for people. For the research material, see the tirzepatide research overview.
| Brand pharmaceutical products | Research-grade tirzepatide | |
|---|---|---|
| Manufacturer | Eli Lilly and Company | Independent research-chemical suppliers |
| Regulatory status | FDA-approved pharmaceutical | Not a drug; laboratory research only |
| Intended context | Clinical, under medical supervision | In-vitro and laboratory research |
| Documentation | Pharmaceutical quality system | Supplier certificate of analysis for the lot |
| Affiliation with V8 Peptides | None | Listed on the V8 Peptides product page |
Molecular identity
Tirzepatide has an average molecular weight of approximately 4,813.52 Da and the molecular formula C225H348N48O68; the V8 Peptides product page lists the same formula. The CAS number is 2023788-19-2. Its 39-residue backbone is based on native GIP, with Aib (aminoisobutyric acid) substitutions, including at position 2, which confers resistance to cleavage by dipeptidyl peptidase-IV, and a C20 fatty-diacid conjugated at Lys20 through a gamma-glutamyl/mini-PEG linker. The fatty diacid supports albumin binding and a long circulating half-life in the intact pharmaceutical context; in the laboratory it mainly matters because it makes the molecule more hydrophobic and more complicated to characterize than an unmodified peptide. The ~700 Da mass difference relative to semaglutide, together with the distinct dual-receptor design, makes the two peptides straightforward to distinguish analytically.
| Feature | Detail |
|---|---|
| Length | 39 amino acids |
| Template | Native GIP |
| Non-natural residues | Aib (aminoisobutyric acid), including position 2 |
| Lipidation | C20 fatty diacid at Lys20 via gamma-Glu/mini-PEG linker |
| Average mass | About 4,813.52 Da |
| Formula | C225H348N48O68 |
| CAS number | 2023788-19-2 |
Whether this counts as a "peptide" in the strict sense is a fair question given the lipid modification; see is tirzepatide a peptide.
Dual-receptor design
Tirzepatide's primary sequence gives it high native affinity for the GIP receptor, while engineered substitutions confer meaningful cross-reactivity with the GLP-1 receptor. That is distinct from combining two separate single-receptor peptides in one experiment: one molecule engages both receptors, so receptor occupancy and signaling bias cannot be separated by simply changing the ratio of two agents. This architecture makes tirzepatide a useful reference compound for combined incretin-receptor signaling, alongside triple agonists such as retatrutide, which adds glucagon-receptor activity on the same GIP-based backbone. Background on the receptors is in incretin receptors explained and GLP-1 receptor agonists in research.
Analytical characterization
Research-grade tirzepatide identity and purity are typically confirmed by reversed-phase HPLC and ESI mass spectrometry, with the observed mass consistent with a monoisotopic mass near 4,813.5 Da. LC-MS/MS peptide mapping can confirm the Lys20 acylation site. The V8 Peptides product page lists a purity specification of ≥98% by HPLC. As with all research peptides, reproducibility depends on documented identity and purity; see third-party testing explained and tirzepatide purity testing.
Why a lipidated peptide needs extra care
A C20 diacid chain makes the molecule retain strongly on a C18 column and increases the chance of aggregation and adsorption to surfaces. Unacylated or mis-acylated variants, including acylation at a different lysine, can have nearly the same mass as the intended product, so mass spectrometry alone does not exclude them; this is the reason peptide mapping, which fragments the molecule and locates the modification, is the more decisive test. Mass at the intact level still screens out gross errors, such as the wrong molecule or a missing lipid (a difference of several hundred daltons).
| Technique | What it establishes for tirzepatide |
|---|---|
| RP-HPLC (UV) | Relative purity; separation from unacylated and truncated forms |
| Intact ESI-MS | Mass near 4,813.5 Da; excludes the wrong molecule |
| LC-MS/MS peptide mapping | Sequence coverage and the Lys20 acylation site |
| Net peptide content | How much of the powder is peptide versus water and counter-ions |
Using the name correctly in your records
For lab records and publications, describe the material by its generic name, supplier, lot number and certificate, not by a brand name. Brand names identify a finished pharmaceutical product with its own excipients, strengths and regulatory file, none of which apply to a lyophilized research reagent. Writing "Mounjaro" or "Zepbound" in a methods section for a research-grade lot would misidentify the material. The accurate description is the compound name, the V8 Peptides lot number, and the measured purity and mass from the certificate on the certificate of analysis page.
The same principle applies to related comparisons. For a research-chemistry comparison of tirzepatide with its sibling compounds, see semaglutide vs. tirzepatide, the parallel semaglutide brand chemistry reference and retatrutide vs. tirzepatide.
Why the distinction matters for reproducibility
Two materials that share an active ingredient name are not interchangeable inputs to an experiment. A finished pharmaceutical product contains excipients, buffers and a fill designed for a different purpose, and its quality system is documented in a regulatory file that a laboratory buyer never sees. A research lot is characterized by whatever analytical record accompanies it, so that record is the only basis for comparing one lot to another. Reproducibility therefore rests on what the certificate says about purity, mass and test date, and on whether the lot number on the vial matches it. If an experiment's results are later compared with literature that used another source of tirzepatide, the comparison should note the source and its characterization instead of assuming equivalence.
Handling research-grade tirzepatide
The product page lists tirzepatide as a 30 mg lyophilized powder in a sealed glass vial, with storage at 2–8 °C and −20 °C for long-term storage, protected from heat, moisture and light. Concentration arithmetic is straightforward: 30 mg dissolved in 3 mL gives 10 mg/mL, and the calculator handles other volumes. More detail on lab handling is in tirzepatide reconstitution and handling, tirzepatide storage and stability and what lyophilization is. For sourcing, see where to buy tirzepatide.
Research use only
Tirzepatide sold by V8 Peptides is intended strictly for laboratory and in-vitro research by qualified researchers. It is not for human or animal consumption, and it is not a substitute for, nor equivalent to, any FDA-approved medication. Questions about approved pharmaceutical products belong with a licensed physician or pharmacist.
Tirzepatide vs. Mounjaro & Zepbound FAQ
Is research tirzepatide the same as Mounjaro or Zepbound?
No. Those are Eli Lilly's FDA-approved pharmaceutical products. Research-grade tirzepatide is a separate laboratory reagent that Lilly does not make, distribute or endorse.
Does V8 Peptides have any affiliation with Eli Lilly?
No. V8 Peptides has no affiliation, partnership or commercial relationship with Eli Lilly or either brand.
What is tirzepatide's molecular weight and formula?
About 4,813.52 Da and C225H348N48O68. The V8 Peptides product page lists the same formula.
What makes the structure unusual for a peptide?
It has 39 residues based on GIP, Aib substitutions for DPP-IV resistance, and a C20 fatty diacid at Lys20 attached through a gamma-Glu/mini-PEG linker.
How is it distinguished from semaglutide analytically?
By mass: tirzepatide is about 700 Da heavier, and its sequence and receptor design differ.
Why is peptide mapping used?
Intact mass cannot rule out a lipid attached at a different lysine, since the mass would be nearly identical. LC-MS/MS mapping locates the modification.
How should this material be named in a methods section?
By generic name, supplier, lot number and measured purity and mass, not by a brand name.
What size vial does V8 Peptides list?
A 30 mg lyophilized vial with a purity specification of at least 98% by HPLC, with a lot-specific certificate linked from the product page.
For laboratory research use only; not for human consumption. This article is research education, not usage guidance.
References
- Tirzepatide research overview
- Tirzepatide purity testing
- Incretin receptors explained
- Third-party testing explained
- Certificate of analysis page
- Tirzepatide product page
Research Use Only. Supplied strictly for laboratory research and development; not for human or veterinary use, consumption, or any clinical or diagnostic purpose.